×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APVO – aptevo therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
03:08 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/11
08:20 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
Medium
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
11/11
08:05 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
High
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
11/7
08:05 am
apvo
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
High
Report
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
11/7
02:04 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/30
02:07 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/29
08:05 am
apvo
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
High
Report
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
10/24
02:42 am
apvo
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
Medium
Report
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
03:46 pm
apvo
Form SC 13G/A Aptevo Therapeutics Inc. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A Aptevo Therapeutics Inc. Filed by: ARMISTICE CAPITAL, LLC
11/8
02:58 pm
apvo
Form SC 13G Aptevo Therapeutics Inc. Filed by: Hudson Bay Capital Management LP
Low
Report
Form SC 13G Aptevo Therapeutics Inc. Filed by: Hudson Bay Capital Management LP
11/7
08:33 am
apvo
Form 10-Q Aptevo Therapeutics Inc. For: Sep 30
High
Report
Form 10-Q Aptevo Therapeutics Inc. For: Sep 30
11/7
08:15 am
apvo
Form 8-K Aptevo Therapeutics Inc. For: Nov 07
High
Report
Form 8-K Aptevo Therapeutics Inc. For: Nov 07
11/4
06:01 am
apvo
Form 8-K Aptevo Therapeutics Inc. For: Nov 01
Medium
Report
Form 8-K Aptevo Therapeutics Inc. For: Nov 01
10/25
04:30 pm
apvo
Form 8-K Aptevo Therapeutics Inc. For: Oct 25
Low
Report
Form 8-K Aptevo Therapeutics Inc. For: Oct 25
10/3
04:46 pm
apvo
Form DEF 14A Aptevo Therapeutics Inc. For: Oct 25
Low
Report
Form DEF 14A Aptevo Therapeutics Inc. For: Oct 25
9/23
04:49 pm
apvo
Form PRE 14A Aptevo Therapeutics Inc. For: Oct 25
Low
Report
Form PRE 14A Aptevo Therapeutics Inc. For: Oct 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/10
Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
20.5%
3/16 Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial 19.1%
4/13 Form 8-K Aptevo Therapeutics Inc. For: Apr 13 15.2%
10/3 Form 8-K Aptevo Therapeutics Inc. For: Oct 03 11.6%
3/18 Aptevo Therapeutics Inc (NASDAQ: APVO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
11/4 Form 8-K Aptevo Therapeutics Inc. For: Nov 01 8.8%
2/28 Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million 7.5%
11/8 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting 7.4%
4/23 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.7%
8/19 Form 4 Aptevo Therapeutics Inc. For: Aug 16 Filed by: Maddux Randy Joe 5.6%
3/16 Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial 19.1%
4/13 Form 8-K Aptevo Therapeutics Inc. For: Apr 13 15.2%
10/3 Form 8-K Aptevo Therapeutics Inc. For: Oct 03 11.6%
3/18 Aptevo Therapeutics Inc (NASDAQ: APVO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
11/4 Form 8-K Aptevo Therapeutics Inc. For: Nov 01 8.8%
2/28 Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million 7.5%
11/8 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting 7.4%
4/23 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.7%
8/19 Form 4 Aptevo Therapeutics Inc. For: Aug 16 Filed by: Maddux Randy Joe 5.6%
TOP News Decliners
2/13
Form SC 13G/A Aptevo Therapeutics Inc. Filed by: RENAISSANCE TECHNOLOGIES LLC
-20.0%
3/13 Form 8-K Aptevo Therapeutics Inc. For: Mar 11 -14.5%
8/12 Form 424B5 Aptevo Therapeutics Inc. -13.5%
3/2 Form 8-K Aptevo Therapeutics Inc. For: Feb 28 -12.3%
1/31 Form PRE 14A Aptevo Therapeutics Inc. For: Mar 11 -12.0%
8/9 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.380 ActVsEst 0.080 - Beat -11.2%
3/5 Aptevo Therapeutics Inc (NASDAQ: APVO) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.0%
10/16 Form 8-K Aptevo Therapeutics Inc. For: Oct 11 -6.9%
3/25 Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update -6.9%
7/25 Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials -6.4%
3/13 Form 8-K Aptevo Therapeutics Inc. For: Mar 11 -14.5%
8/12 Form 424B5 Aptevo Therapeutics Inc. -13.5%
3/2 Form 8-K Aptevo Therapeutics Inc. For: Feb 28 -12.3%
1/31 Form PRE 14A Aptevo Therapeutics Inc. For: Mar 11 -12.0%
8/9 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.380 ActVsEst 0.080 - Beat -11.2%
3/5 Aptevo Therapeutics Inc (NASDAQ: APVO) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.0%
10/16 Form 8-K Aptevo Therapeutics Inc. For: Oct 11 -6.9%
3/25 Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update -6.9%
7/25 Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials -6.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: